Tilray Brands (TLRY) Cost of Revenue (2017 - 2026)
Tilray Brands (TLRY) posted Cost of Revenue of $151.8 million for Q1 2026, up 1188.33% on a QoQ basis from $11.8 million in Q4 2025, and up 13.46% year-over-year from $133.8 million in Q1 2025.
Tilray Brands (TLRY) Cost of Revenue (2017 - 2026) Analysis & Trends
Tilray Brands' Cost of Revenue history runs 10 years deep, the most recent figure standing at $151.8 million for Q1 2026.
- Quarterly Cost of Revenue rose 13.46% year-over-year to $151.8 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$191.3 million (down 123.01% YoY) and the FY2025 annual result came in at $56.0 million, down 90.09% from the prior year.
- Cost of Revenue was $151.8 million for Q1 2026 at Tilray Brands, up from $11.8 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $541.2 million in Q2 2024 and bottomed at -$367.8 million in Q2 2025.
- A 5-year average of $98.4 million and a median of $104.6 million in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 1413.72% — and 2025, when it sank 167.97%.
- Tilray Brands' Cost of Revenue stood at $9.7 million in 2022, then soared by 1413.72% to $146.4 million in 2023, then slumped by 88.96% to $16.2 million in 2024, then retreated by 27.11% to $11.8 million in 2025, then jumped by 1188.33% to $151.8 million in 2026.
- Business Quant data shows TLRY's Cost of Revenue at $151.8 million in Q1 2026, $11.8 million in Q4 2025, and $12.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | 151.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 151.78 Mn |
| Feb 28, 2026 | 151.78 Mn |
| Nov 30, 2025 | 11.78 Mn |
| Nov 30, 2025 | 11.78 Mn |
| Aug 31, 2025 | 12.92 Mn |
| Aug 31, 2025 | 12.92 Mn |
| May 31, 2025 | -367.80 Mn |
| May 31, 2025 | -367.80 Mn |
| Feb 28, 2025 | 133.77 Mn |
| Feb 28, 2025 | 133.77 Mn |
| Nov 30, 2024 | 16.16 Mn |
| Nov 30, 2024 | 16.16 Mn |
| Aug 31, 2024 | 140.34 Mn |
| Aug 31, 2024 | 140.34 Mn |
| May 31, 2024 | 541.15 Mn |
| May 31, 2024 | 541.15 Mn |
| Feb 29, 2024 | 10.00 Mn |
| Feb 29, 2024 | 10.00 Mn |
| Nov 30, 2023 | 146.36 Mn |
| Nov 30, 2023 | 146.36 Mn |